Dedicated to Understanding and Treating Tinnitus
Neuromonics is a healthcare company dedicated to helping people with tinnitus to improve their quality of life and overcome challenges associated with tinnitus.
We are the manufacturer and distributor of the only U.S. FDA-cleared, patented, customized and clinically proven medical device designed for long-term, significant relief of tinnitus. In addition, we have regulatory approval from the Therapeutic Goods Administration (TGA) in Australia.
We employ clinicians experienced in auditory problems who specialize in the treatment of tinnitus disturbance, and provide training for other medical professionals on how to help their patients who experience tinnitus.
Global operations are located in Bethlehem, Pennsylvania, USA and Sydney, Australia.
Our Background
Neuromonics was founded in 2001 to bring a global breakthrough in tinnitus treatment to patients and professionals who previously had few, if any, treatment options.
Developed by Paul Davis, PhD, an Australian clinical audiologist, the Neuromonics Tinnitus Treatment is based on extensive research conducted since the early 1990s and has been proven effective in multiple clinical trials as well as in the "real world" environment of general clinical practice.
Since its introduction in 2004, the patented Oasis™ device and associated treatment has been available in Australia. In late 2005, the Neuromonics treatment was made available in the United States. Currently there have been more than 2,000 patients treated worldwide.
To find a participating provider near you, click here.
About the Inventor
Dr. Paul Davis is the inventor of the Neuromonics Tinnitus Treatment and was, for a number of years, the company's Chief Scientific Officer. He has presented and published research papers for three International Tinnitus Seminars, the Audiology Society of Australia and the American Academy of Audiology. He has also written successful self-help books for tinnitus and hearing loss, and has authored or co-authored numerous articles from his research.
Before focusing his efforts on the area of tinnitus, Dr. Davis led international clinical research programs for Oticon A/S, one of the world’s largest manufacturers of hearing aids.
Board of Directors
Director and Chairman of the Board Ronald E. West:
Ron West has 25 years experience in the medical device industry and is President of Go West Inc., a management consulting firm servicing the medical device Industry. He also serves on the Board of the Deafness Research Foundation, Washington D.C.
Director Mike Quinn:
Michael co-founded Innovation Capital in 1999 and is Managing Partner of the firm. His experience encompasses a broad range of industries including banking, high technology plastics, environmental, electronics and medical device industries in the U.S., Europe and Australia. Michael has advised and mentored numerous companies in operational, strategic and financial matters.
Director Brigitte Smith:
Brigitte Smith has 15 years experience in venture capital, business strategy and technology company operations. Smith has been investing and managing investments for GBS’s $400 million of life science specialized venture capital funds for ten years. In addition to Neuromonics, Smith is on the board of GBS portfolio companies, Applied Physiology, Cortical, Dynamic Hearing, Kalobios Inc, and Proacta Therapeutics Inc.
Director and CEO Rick Giancola:
Rick Giancola has 28 years of experience in various sales, marketing, operations and manufacturing positions, including leadership roles, with American Hospital Supply, Deseret Medical, Spectramed and Cochlear Americas. He founded Landmark Medical Exports, Inc., an Export Management and Consulting company representing manufacturers of medical devices and equipment wishing to sell their products in Latin America. Giancola joined Neuromonics as Global CEO in May 2008.
About Our Investors
GBS Venture Partners:
GBS Venture Partners is an Australian-based life science specialist venture capital firm, with over $400M under management. With offices in Melbourne and Sydney, GBS has invested in more than 30 private and public companies. GBS invests in and helps build life science companies which involve Australasian operations or technology on both sides of the Pacific. GBS team members take active roles at the board level of their portfolio companies. Additionally, GBS brings a significant international network of corporate collaborators and investors to further the prospects of portfolio companies. For more information about GBS Venture Partners go to www.gbsventures.com.au.
Innovation Capital:
Innovation Capital is a leading Australian venture capitalist with offices in Australia and the United States. Innovation Capital is an early stage, diversified fund manager, investing across both physical and life sciences. The firm invests in businesses based on innovative Australian technology and unique intellectual property which present global opportunities in the medical device, telecommunications, IT, engineering, cleantech and biotech sectors. Innovation Capital's team comprises entrepreneurs and executives with exceptional track records in founding and building technology-driven businesses which have become leaders in their fields. Innovation Capital brings decades of real-world entrepreneurial experiences to the active, hands-on support of their investee companies; to manage risk, maximize investor returns and to help nurture their companies on their path to becoming globally successful businesses. For more information about Innovation Capital go to www.innovationcapital.net.
Neuromonics Global Locations
Neuromonics, Inc. – Global Headquarters
2810 Emrick Boulevard
Bethlehem, PA 18020
United States of America
Telephone: 1-866-606-3876
Email: info@neuromonics.com
Neuromonics Pty. Ltd.
Level 2, 12 Thomas Street
Chatswood, NSW, 2067
Australia
Telephone: +61 (2) 9410-4300 or 1300 367 907
Email: customerservice@neuromonics.com